About Dr. Han Baohui
Dr. Han Baohui (韩宝惠) is Chief Physician, Professor, and Director of the Department of Pulmonary Medicine and Medical Oncology at Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine — China's premier thoracic specialty hospital and the national leader in lung cancer diagnosis and treatment. He is one of China's foremost authorities on lung cancer medical oncology, with particular expertise in targeted therapy, immunotherapy, and the precision treatment of advanced non-small cell lung cancer (NSCLC).
Dr. Han has dedicated his career to advancing the systemic treatment of lung cancer in China, leading landmark clinical trials that have established new standards of care for EGFR-mutant NSCLC, ALK-rearranged lung cancer, and immunotherapy in PD-L1-expressing tumors. His clinical program at Shanghai Chest Hospital manages one of the highest volumes of lung cancer patients in China, providing access to the full spectrum of approved targeted agents and immunotherapy combinations as well as early-phase clinical trials of novel therapeutics.
Hospital Affiliation
Shanghai Chest Hospital is China's most specialized and highest-volume thoracic disease center, dedicated exclusively to the diagnosis and treatment of diseases of the chest including lung cancer, esophageal cancer, mediastinal tumors, pleural disease, and thoracic surgery. The hospital's lung cancer program — integrating medical oncology, thoracic surgery, radiation oncology, interventional pulmonology, and pathology — is consistently ranked first in China and manages a case volume that is among the highest in Asia. The multidisciplinary tumor board at Shanghai Chest Hospital reviews complex lung cancer cases daily, ensuring that every patient receives a treatment plan informed by the full breadth of oncological expertise.
Clinical Expertise
- EGFR-mutant NSCLC — first, second, and third-generation EGFR TKI therapy (gefitinib, erlotinib, afatinib, osimertinib); T790M resistance management; osimertinib resistance mechanisms and subsequent therapy; exon 20 insertion mutations
- ALK/ROS1/RET-rearranged NSCLC — ALK TKI therapy (crizotinib, alectinib, brigatinib, lorlatinib); resistance management; ROS1 and RET inhibitor therapy
- Immunotherapy — PD-1/PD-L1 inhibitor therapy (pembrolizumab, nivolumab, atezolizumab, sintilimab, camrelizumab); chemo-immunotherapy combinations; immunotherapy toxicity management; biomarker-driven patient selection (PD-L1, TMB, MSI)
- KRAS/MET/BRAF-mutant NSCLC — KRAS G12C inhibitors; MET exon 14 skipping mutations; BRAF V600E-mutant NSCLC
- Small cell lung cancer (SCLC) — extensive-stage SCLC; chemo-immunotherapy; second-line therapy; prophylactic cranial irradiation
- Malignant pleural mesothelioma — diagnosis and staging; systemic therapy; immunotherapy combinations
- Clinical trial access — early-phase trials of novel targeted agents and immunotherapy combinations; expanded access programs
Academic & Research Contributions
Dr. Han Baohui is one of China's most prolific lung cancer researchers, with an extensive publication record in leading oncology journals including Journal of Clinical Oncology, Annals of Oncology, Lancet Oncology, and JAMA Oncology. He has served as principal investigator on multiple landmark phase III clinical trials that have established new standards of care for targeted therapy and immunotherapy in Chinese lung cancer patients, and his research has been presented at major international oncology conferences including ASCO, ESMO, and WCLC.
He serves in leadership positions in the Chinese Society of Clinical Oncology (CSCO) Lung Cancer Committee and contributes to the development of national clinical practice guidelines for lung cancer treatment in China. He is a frequent invited speaker at major international lung cancer conferences and maintains active research collaborations with leading oncology centers globally.
Why International Patients Choose Dr. Han Baohui
Lung cancer is the most common cancer diagnosis worldwide and the leading cause of cancer death. For international patients with advanced NSCLC — particularly those with actionable driver mutations (EGFR, ALK, ROS1, KRAS, MET, RET, BRAF) or those being considered for immunotherapy — Dr. Han's program at Shanghai Chest Hospital offers access to the full spectrum of approved targeted agents and immunotherapy combinations, as well as early-phase clinical trials of novel therapeutics that may not yet be available in the patient's home country.
Many international patients seek Dr. Han's expertise for second opinions on treatment strategy after progression on first-line therapy, access to next-generation targeted agents for resistance mutations, evaluation for clinical trial eligibility, and management of immunotherapy toxicity. Treatment costs at Shanghai Chest Hospital are substantially lower than equivalent oncological care in Western healthcare systems, with no compromise in drug quality, monitoring standards, or oncological expertise.
What to Expect at Your Consultation
Consultations with Dr. Han begin with a comprehensive oncological assessment including review of pathology reports (including molecular profiling — EGFR, ALK, ROS1, KRAS, PD-L1, TMB, NGS panel), prior imaging (CT, PET-CT), treatment history, and current performance status. CMCS will arrange certified translation of all prior medical records and pathology reports in advance. Dr. Han will provide a definitive assessment of treatment options, recommend molecular testing if not yet performed, and outline a personalized treatment plan. A written English-language consultation summary is provided after every appointment.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking lung cancer medical oncology care with Dr. Han Baohui at Shanghai Chest Hospital, including priority appointment scheduling, certified medical translation, molecular pathology coordination, prior imaging review, and written English consultation summary. Contact us at contact@medicalsh.com, , or visit medicalsh.com.
0 則留言